Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 65862-249

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 65862-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Alfuzosin Fig1)

This appears to be a graph displaying the plasma concentration of Alfuzosin over time (in hours). Without additional context or further information, it is difficult to provide a more detailed description or analysis.*

FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

The text appears to be a partial excerpt from a medical research article or report. It includes a comparison of the effectiveness of a placebo treatment versus a drug called Alfuzosin hydrochloride in reducing symptoms measured by IPSS Total Symptom Score. The mean change in symptoms over time is represented graphically in Figure 2 and the statistical significance of the results is indicated by p<0.001.*

FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

This is a graph showing the mean change from baseline in IPSS Total Symptom Score for Trial 2, with days of treatment on the X-axis and Hycom on the Y-axis. The text at the beginning appears to be random characters and is not readable.*

FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

The text is a partial description of a figure showing the mean change from baseline in peak urine flow rate in days of treatment of a certain trial.*

FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

The text appears to be a graph that shows the Mean Change from Baseline in Peak Urine Flow Rate (uL/s) for Trial 3 after a treatment period of 20 days. The values on the x-axis were not included in the text. Therefore, a proper description cannot be provided.*

FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablet Bottle))

This is a description of a medication named Alfuzosin Hydrochloride Extended-Release Tablets USP, which contains 10mg Alfuzosin Hydrochloride USP. The medication is distributed by Aurobindo Pharma USA, Inc. and comes in a package of 30 tablets. The usual dosage is mentioned in the package insert. The medication should be stored in a tight and light-resistant container between 20° to 25°C (68° to 77°F); with excursions permitted to 15° to 30°C (59° to 86°F). It should be kept out of reach of children and protected from light and moisture. The code TS/DRUGS/19/1993 is also mentioned. Made in India.*

FDA Label Image

Structure (Alfuzosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.